Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Michelle Ramsberger

Physician Assistant Bethlehem, PA Physician Assistant

NPI 1417953753 CMS profile 10536532

940 N New St, Bethlehem, PA 18018

Open in the dashboard

General payments

$6,373

362 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michelle Ramsberger of Bethlehem, PA is reported in the CMS Open Payments database as having received $6,373 across 362 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,222 107
2024 General $1,767 104
2023 General $1,521 83
2022 General $42 3
2021 General $821 65

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michelle Ramsberger
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Michelle Ramsberger were reported at $2,222. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Michelle Ramsberger Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $821 $132 $37–$438 $132
2022 $42 $155 $48–$522 $149
2023 $1,521 $167 $52–$557 $160
2024 $1,767 $178 $55–$600 $164
2025 $2,222 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $1,819 132 payments
  2. AbbVie, Inc. $748 51 payments
  3. Sun Pharmaceutical Industries Inc. $517 24 payments
  4. Amgen Inc. $422 20 payments
  5. UCB, Inc. $411 17 payments
  6. Galderma Laboratories, L.P. $312 14 payments
  7. E.R. Squibb & Sons, L.L.C. $226 15 payments
  8. LEO Pharma Inc. $225 10 payments
  9. Lilly USA, LLC $211 12 payments
  10. Regeneron Healthcare Solutions, Inc. $198 8 payments
  11. Other $1,284 59 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,941 354 payments
  2. Education $432 8 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $1,787 124 payments
  2. SKYRIZI Immunology $521 33 payments
  3. Otezla $422 20 payments
  4. Bimzelx $354 14 payments
  5. DUPIXENT $323 10 payments
  6. NEMLUVIO $279 12 payments
  7. SOTYKTU $226 15 payments
  8. ILUMYA $212 15 payments
  9. SKYRIZI Immunology $188 15 payments
  10. TALTZ $171 10 payments
  11. Other $2,082 131 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

800

Median for Physician Assistant: 241

Drug cost

$118,535

Median for Physician Assistant: $4,110

Branded share of claims

20.5%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Enbrel Sureclick Etanercept Brand 13 $95,772
Clobetasol Propionate Generic 69 $2,583
Metronidazole Generic 36 $2,111
Doxycycline Hyclate Generic 43 $1,981
Ciclopirox Ciclopirox Olamine Brand 71 $1,676
Triamcinolone Acetonide Generic 99 $1,603
Azelaic Acid Generic 15 $1,419
Fluocinonide-E Fluocinonide/Emollient Base Brand 24 $1,360
Fluocinonide Generic 19 $1,241
Valacyclovir Valacyclovir Hcl Brand 26 $1,087

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
$587 — —
SKYRIZI
$230 — —
SOTYKTU
$147 — —
Otezla
$133 — —
Bimzelx
$127 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

362 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record